Research programme: epithelial stem cell therapies - EpiStem

Drug Profile

Research programme: epithelial stem cell therapies - EpiStem

Alternative Names: Epi 1461; Epi 2499; Epi 3423; Epi 5417; Epi 5539; Epi 5540

Latest Information Update: 28 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EpiStem
  • Developer Epistem
  • Class
  • Mechanism of Action Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Gastrointestinal disorders; Wounds

Most Recent Events

  • 28 Apr 2015 Preclinical development of the candidates is ongoing
  • 28 Apr 2015 Research programme: epithelial stem cell therapies - EpiStem is available for licensing as of 30 Jun 2014. http://www.epistem.co.uk/
  • 03 Aug 2007 Preclinical trials in Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top